Gilead Sciences, Inc. acquires CymaBay Therapeutics, Inc. for USD 4,300,000,000 (2024)

Deal facts

Buyer: Gilead Sciences, Inc.
Target: CymaBay Therapeutics, Inc.
Deal value: USD 4,300,000,000
Announced: 12 February 2024
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

22 Mar 2024CompletedClosed
Gilead Sciences, Inc. completes acquisition of CymaBay Therapeutics, Inc.
Introductory Note. As previously disclosed on February 12, 2024 in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) by CymaBay Therapeutics, Inc., a Delaware corporation (the “ Company ”), the Company entered into an Agreement and Plan of Merger, dated as of February 11, 2024 (the “ Merger Agreement ”), by and among the Company, Gilead Sciences, Inc.,
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of CymaBay Therapeutics by Gilead Sciences for 4.3 billion USD. This transaction, announced on 12 February 2024 and settled in cash, represents a classic consolidation move within the US healthcare sector. The buyer has chosen a straightforward all-cash structure to take the target private, removing the volatility of public markets for CymaBay shareholders. This approach signals confidence in the underlying assets and a desire to integrate the target without the distraction of quarterly reporting pressures.

For the SME founder watching from the UK or elsewhere, the mechanics here offer a useful blueprint for understanding how strategic buyers operate when they want speed and certainty. The use of a single cash consideration eliminates the risk of earn-out disputes or share-price fluctuations that often plague mixed-consideration deals. In the US context, a deal of this size would have triggered a mandatory review by the Federal Trade Commission or the Department of Justice under Hart-Scott-Rodino filing requirements. The fact that the deal is marked as completed suggests that any competition concerns were either non-existent or resolved quickly, allowing the transaction to close without prolonged regulatory drag. This efficiency is often what makes cash deals so attractive to sellers who want a clean exit.

The decision to take a biotech firm private also highlights a shift in how large pharma companies view innovation. Rather than building everything internally, they are acquiring established platforms to fill pipeline gaps immediately. This reduces the time-to-market for new therapies and allows the acquirer to leverage its existing commercial infrastructure. The all-cash nature of the deal removes any ambiguity about the value being transferred, providing immediate liquidity to the target shareholders. It is a blunt instrument, but one that works when the strategic fit is strong and the regulatory path is clear.

You should review your own cap table and identify any shareholders who might prefer a clean cash exit over a complex equity roll-over. If your business operates in a regulated sector, prepare your competition law filing documentation now, as this will be the first hurdle any serious buyer will raise during due diligence.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More going private deals More from Gilead Sciences, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history